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Introduction:  This study aimed to compare the prevalence of
diabetes mellitus (DM) between Sami and non-Sami inhabitants of
Northern Norway participating in the SAMINOR 1 Survey and the
SAMINOR 2 Clinical Survey, and to track DM prevalence over time.
Methods:  SAMINOR 1 (2003–2004) and SAMINOR 2 (2012–2014)
are cross-sectional, population-based studies that each recruited
Sami and non-Sami inhabitants. The data used in this article were
restricted to participants aged 40–79 years in 10 municipalities in
Northern Norway. Participants completed self-administered
questionnaires and underwent clinical examination and blood
sampling. Both questionnaire information and non-fasting/random
plasma glucose levels were used to ascertain DM. The study
included 6288 and 5765 participants with complete data on DM
and outcomes, ie 54.6% and 46.3% of the invited samples,
respectively.
Results:  No difference in the prevalence of DM between Sami and
non-Sami participants was observed, in either survey. Women had
a statistically significantly lower DM prevalence than men in
SAMINOR 2. Mean waist-to-height ratio and waist circumference
increased substantially in both sexes; mean body mass index
increased only slightly in men and remained unchanged in women.
The total, age-standardized DM prevalence in SAMINOR 1 and 2
was 10.0% (95% confidence interval (CI) 9.2–10.7) and 11.2%
(95%CI 10.4–12.0), respectively, and the proportion of self-
reported (ie known) DM increased from 49.2% to 73.0%. In almost
the same time span (2004–2015), the use of oral glucose-lowering
agents increased.
Conclusion:  Overall, no ethnic difference was observed in DM
prevalence. Overall DM prevalence was high, but did not change
significantly from SAMINOR 1 to SAMINOR 2. The percentage of
known versus unknown cases of DM increased, as did the
prescription of medication for DM between 2004 and 2015.
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FULL ARTICLE:
Introduction
Diabetes mellitus (DM) is a chronic disease, which has evolved into
a global challenge and a burden on healthcare services . DM has
reached epidemic proportions in both low- and high-income
countries in the past few decades . There has been no nationwide
survey on the prevalence of type 2 DM (T2DM) in Norway;
however, in 2004 it was estimated at around 3.4% in adults aged
30 years and older . The prevalence of all types of DM in the first
survey of the Population-based Study on Health and Living
Conditions in Regions with Sami and Norwegian Populations (the
SAMINOR 1 Survey, 2003–2004) was 4.6% among inhabitants of
rural areas in Northern and Middle Norway, with a remarkable
heterogeneity across different geographical regions ; prevalence
was higher among the Sami in southern municipalities and
generally lower further north.
The Sami are an indigenous people who constitute an ethnic
minority in the northern parts of Norway, Sweden and Finland, as
well as in Russia’s Kola Peninsula. In Norway, the traditional Sami
settlement area stretches from Finnmark County in the north to
Engerdal in Hedmark County in the south. The number of
Norwegian Sami has been estimated between 40 000 and 50 000 .
Although this estimate has major limitations, no updated, reliable
estimates exist. The Sami people harbor a rich variety of cultures,
habits, rituals, languages, and livelihoods. Northern Norway is also
home to the Kvens, an ethnic group with a long-standing
attachment to that region. The Kvens are descendants of Finnish-
speaking settlers who immigrated from Sweden and Finland in the
1700s and 1800s  and were recognized as a national minority in
1998 .
There is a lack of comprehensive information on health status and
on the chronic and lifestyle-related disease burden among various
ethnic groups in Northern Norway. However, numerous studies
have reported an increasing prevalence of lifestyle-related diseases
among indigenous populations in other countries . Therefore,
this study aimed to compare the prevalence of DM between Sami
and non-Sami inhabitants of Northern Norway participating in the
SAMINOR 1 Survey and the SAMINOR 2 Clinical Survey, and to
track DM prevalence over time.
Methods
In 2003–2004, the Centre for Sami Health Research at UiT The
Arctic University of Norway, in collaboration with the Norwegian
Institute of Public Health, undertook the SAMINOR 1 Survey
(hereafter referred to as SAMINOR 1) . This survey included
24 mostly rural municipalities and districts in Northern and Middle
Norway, where the proportion of inhabitants belonging to the
Sami ethnic group is high according to ethnic and language
information registered in the 1970 census, and historical and local
knowledge about traditional Sami settlement regions. Information
from the National Registry was used to invite inhabitants aged 30
and 36–79 years to participate, regardless of their ethnic group.
The single cohort of 30-year-olds were invited due to collaboration
with a regional screening of certain cohorts. Data were collected
through self-administered questionnaires, a clinical examination,
and analysis of blood samples.
The Centre for Sami Health Research conducted a second clinical
survey, the SAMINOR 2 Clinical Survey (hereafter referred to as
SAMINOR 2), in 2012–2014, which consisted of self-administered
questionnaires, a clinical examination, and analysis of blood
samples. Individuals aged 40–79 years were included from
10 municipalities in Finnmark, Troms, and Nordland counties.










Karasjok, Kautokeino, Porsanger, Tana, Nesseby, Lyngen, Storfjord, Kåfjord, Evenes, Skånland (Fig1).
Figure 1:  Map of Northern Norway, Sápmi, and the included municipalities in SAMINOR 1 and 2.
Study sample
The present analyses are based on cross-sectional data from two
points in time of inhabitants aged 40–79 years residing in the
10 municipalities included in both SAMINOR 1 and SAMINOR 2.
In SAMINOR 1, 11 518 inhabitants aged 40–79 years from the
10 municipalities were invited, and 6587 underwent clinical
examinations (57.2%). Of the 6587 eligible participants, 175 people
who did not complete the questionnaire that collected information
on ethnicity, 14 with missing plasma glucose values, 86 foreigners,
and 27 with unknown ethnicity were excluded, leaving
6285 participants (54.6%) in the present analyses.
In SAMINOR 2, 12 455 inhabitants aged 40–79 years from the
10 municipalities were invited, and 6004 participated (48.2%). Of
the 6004 eligible participants, 21 who did not complete the
questionnaire that collected information on ethnicity, 25 with
missing plasma glucose values, 96 foreigners, and 97 with
unknown ethnicity were excluded, leaving 5765 (46.3%) individuals
in the present analyses.
Data collection
In both SAMINOR 1 and 2, an invitation was mailed several weeks
before the survey with information on the time and place of
screening, relevant and required information about the survey, and
questionnaires. The questionnaires were returned by the
participants at the time of the clinical examination .
In SAMINOR 1, all participants received three self-administered
questionnaires (nine pages in total): An initial questionnaire that
contained a variety of questions, including questions about
ethnicity; a screening questionnaire that collected information
about symptoms, lifestyle factors, and some diseases, including
DM; and an additional questionnaire that collected cultural, social,
and nutritional information. The questionnaires were prepared in
Norwegian and translated into the three main Sami languages.
Almost 97% of the participants in the present study completed the
Norwegian version of the questionnaire. The clinical examination
was carried out in two buses that moved throughout the study
area, spending 1–6 weeks in each of the municipalities included in
this analysis . In 9 of the 10 municipalities, non-responders got a
second chance to attend when the buses returned a couple of
months later.
In SAMINOR 2, participants aged 40–69 years received an eight-
page questionnaire with a broad range of questions on lifestyle,
diet, risk factors, and diseases. A shorter questionnaire (four pages
with larger fonts) was sent to inhabitants aged 70–79 years. The
questionnaires were prepared in Norwegian and translated into
the Northern Sami language. Less than 5% of participants chose to
use the Sami questionnaire. The clinical examination was
performed at 10 temporarily established health examination sites
in nine municipalities. In each municipality, data collection was
carried out within 2–7 weeks.
In both SAMINOR 1 and 2, height and weight were measured
using an electronic height and weight scale, with participants
wearing light clothing without shoes. Body mass index (BMI) was
calculated as weight in kilograms divided by the square of the
height in meters (kg/m ). Waist circumference (WC) was measured
at the umbilicus with the participant standing and breathing
normally. Waist-to-height ratio (WHtR) was calculated by dividing
waist circumference by height both in centimeters. Finally, non-
fasting blood samples were taken by venipuncture at normal
venous pressure with the participant in a seated position and used
to determine blood glucose. In SAMINOR 1, blood samples were
sent by post directly to the laboratory and analysed consecutively.
In SAMINOR 2, blood samples were initially frozen and sent to the
laboratory later.
The Norwegian Prescription Database




Institute of Public Health (NIPH) contains a complete listing of all
prescribed drugs dispensed by pharmacies in Norway from 1
January 2004 . NIPH provided information on the number of
users (per 1000) who were given a drug with Anatomical
Therapeutic Classification code A10B in all 10 municipalities for the
years 2004–2015, aggregated by sex and 10-year age groups. A
user was defined as a person who has received at least one
prescription from a pharmacy in Norway in a given year . NPD
data was used as an independent source of information to which
results from SAMINOR data was compared.
Ethnicity
Information on ethnicity was obtained from the questionnaires.
The questions were ‘What language(s) do/did you, your parents
and your grandparents use at home?’, ‘What is your, your father’s
and your mother’s ethnic background?’, and ‘What do you
consider yourself to be?’ On all items the response options were
‘Norwegian’, ‘Sami’, ‘Kven’, and ‘Other’. The questions were to be
answered separately for each relative, and multiple answers were
allowed. Participants were categorized as Sami if they responded
that they either considered themselves to be Sami or reported to
have a Sami ethnic background, and if in addition at least one of
their grandparents, parents, or they themselves spoke a Sami
language at home. All other participants were categorized as non-
Sami.
Diabetes mellitus
Both questionnaire information and non-fasting/random plasma
glucose (RPG) levels were used to categorize participants as having
DM. In SAMINOR 1, the question concerning diabetes was ‘Do you
have or have you had diabetes?’ In SAMINOR 2, the question was
‘Have you ever been diagnosed with diabetes (elevated blood
sugar levels)?’ The available answers were ‘yes’ or ‘no’. Missing
values in SAMINOR 1 (n=349) and 2 (n=136) were classified as ‘no’.
All participants with RPG levels of 7.5 mmol/L or higher were also
classified as having DM, regardless of their reply in the
questionnaire. No distinction was made between different types of
DM (type 1, type 2 or gestational) due to lack of information in
SAMINOR 1.
Statistical analysis
Data management and statistical analysis were done using STATA
version 14.1 (Stata Corp, http://www.stata.com). Differences in age,
BMI, WC and WHtR between ethnic groups and by sex in the two
SAMINOR surveys were assessed using two independent samples
t-tests. Normality of the variables was assessed using distribution
histograms. The direct method was used to age-standardize the
prevalence of DM, using the population invited to SAMINOR 2 as
the standard population. Prevalence of DM was calculated with
95% confidence intervals (CIs) for different sexes, ages, and ethnic
groups. Due to large sample sizes, CIs were calculated based on
normal approximation. Ethnic differences in the prevalence of DM
in each age group and sex were tested by Χ tests. A large number
of participants in SAMINOR 2 also participated in SAMINOR 1.
Because the two samples cannot be assumed to be independent,
no statistical test was performed to compare the total age-
standardized prevalence in the two SAMINOR surveys. However,
overlapping of participants between SAMINOR 1 and 2 in the age
groups 60–69 and 70–79 years, respectively, was less of a problem
as the surveys were conducted 8–11 years apart. For these two age
groups, differences in the prevalence of DM between SAMINOR 1
and SAMINOR 2 for corresponding age, sex and ethnic groups
were tested using a large sample test for difference between two
proportions.
Ethics approval
The SAMINOR Study was approved by the Norwegian Data
Inspectorate and the Regional Committee for Medical and Health
Research Ethics. The committee also approved the present study
with the approval number 2016/173. All included participants gave
written informed consent.
Results
BMI was higher among Sami than non-Sami participants in both
surveys, except for men in SAMINOR 2. On the other hand, WC
was higher among non-Sami men compared to their Sami
counterparts. Although Sami women had statistically significantly
higher WC in SAMINOR 1, this discrepancy was not observed in
SAMINOR 2. WHtR was higher in Sami men and women compared
to their non-Sami counterparts in both surveys. Participants in
SAMINOR 2 were approximately 3 years older than participants in
SAMINOR 1 (Table 1). The mean BMI (regardless of ethnicity)
increased slightly in men but remained almost unchanged in
women, while the mean WC and WHtR increased substantially in
both sexes and in both ethnic groups (Table 1).
In SAMINOR 1, 587 (9.3%) participants were categorized as having
DM. Of these, 289 (4.6% of all participants and 49.2% of those
categorized as having DM) reported having DM in the
questionnaire; the remainder were categorized as having DM due
to RPG levels of 7.5 mmol/L or higher (results not shown). In
SAMINOR 2, 684 (11.9%) participants were categorized as having
DM, of whom 499 (8.7% of all participants and 73.0% of those
categorized as having DM) reported having DM in the
questionnaire (results not shown). The total age-standardized
prevalence of DM in SAMINOR 1 and 2 was 10.0% (95%CI
9.2–10.7) and 11.2% (95%CI 10.4–12.0), respectively (results not
shown).
The total age-standardized prevalence of DM remained fairly
unchanged in both sexes and ethnic groups (Table 2). Regardless
of ethnicity, while there was no sex predilection in the prevalence
of DM in SAMINOR 1, men had a statistically significantly higher
prevalence of DM in SAMINOR 2 (13.1 v 10.9, p=0.01).
For inhabitants aged 40–79 years in the 10 included municipalities,
information from the NPR demonstrated an increase in the
number of people using oral hypoglycemic agents for T2DM in the
period 2004–2015 (Fig2). The increase was most prominent in men
and elderly participants. In 2004, 4.6% of the inhabitants were




using them in 2015. However, the pace of this increase was more stable during the last few years of the study.
Table 1:  Selected characteristics of participants in the SAMINOR 1 Survey (2003–2004) and the SAMINOR 2 Clinical Survey
(2012–2014)
Table 2:  Prevalence of diabetes mellitus in the SAMINOR 1 Survey and the SAMINOR 2 Clinical Survey by sex, age, and ethnicity
Figure 2:  Use of oral glucose-lowering agents over the period 2004–2015 for men and women aged 40–79 years in the
10 municipalities included in the SAMINOR 2 Clinical Survey.
Discussion
Main findings
Overall, no difference in the prevalence of DM by ethnic group was
observed. Total age-standardized prevalence of DM in SAMINOR 1
and 2 were 10.0% (95%CI 9.2–10.7) and 11.2% (95%CI 10.4–12.0),
respectively. In the 10 included municipalities, the number of
people using oral hypoglycemic agents increased in the period
2004–2015. For both ethnic groups, mean WC and WHtR increased
substantially in both sexes.
Increase in the proportion of diagnosed cases of DM:  In 2015,
the International Diabetes Federation estimated that around half
of adults with T2DM worldwide were undiagnosed . Although the
total age-standardized prevalence of DM was similar in SAMINOR
1 and 2, the percentage of self-reported (ie known) cases of DM
increased from 49.2% of total diabetics to 73.0%. The results are in
accordance with findings of increased T2DM treatment in the NPD
in the same municipalities. A plausible explanation may be higher
awareness of DM in the general population and among healthcare
providers, as well as more accessible diagnostic procedures. Strøm
et al. reported that the number of people starting glucose-
lowering agents between 2006 and 2011 in Norway remained
rather consistent, at 16 000 new cases each year . This number
applies to all of Norway and does not take into account
undiagnosed cases of T2DM, or those who manage it by diet
and/or physical activity alone. The unchanged prevalence of DM in
the present study may be attributable to the rather constant
characteristics and demographic composition of the study
population. It may take more time for the increase in abdominal
obesity (WC and WHtR) observed between SAMINOR 1 and 2 to
show its effects. On the other hand, this increase in WC and WHtR
may have been compensated for by other factors such as
enhanced physical activity. Unfortunately, there is lack of
comparable information on physical activity and therefore it is not
possible to assess whether physical activity levels changed in the
period between the two SAMINOR surveys. As DM is a chronic
disease that develops over a long period of time, one could expect
that any changes in predisposing or protective factors would have
a gradual effect, with resultant changes observed first in the
prevalence of pre-diabetes.
No ethnic difference in the prevalence of DM:  Similar to
previous SAMINOR 1 publications including all 24 municipalities,
no overall difference in the prevalence of DM between Sami and
non-Sami populations was found in this study . A relatively
similar and homogeneous prevalence of DM among Sami and
non-Sami inhabitants in Northern Norway may imply a similar
lifestyle and equal access to healthcare information and services,





municipalities in the present survey were heterogeneous in terms
of location, climate, ethnic composition of inhabitants, severity of
assimilation and so-called Norwegianization policies in the past
decades, inhabitants’ profession, diet, cultures and language.
DM among other indigenous peoples worldwide:  Publications
on the prevalence of DM in other Arctic indigenous peoples aged
40–79 years are scarce. In 1999–2001, the prevalence of DM
among Inuit migrants in Denmark aged 35 years and above was
10.2% . In 2007–2008, the prevalence of self-reported DM among
the Inuit population in Canada aged 50 years and older was
12.2% . These prevalence figures are similar to the present results.
However, methods of determining diabetes cases differed. A
recent study based on self-reported disease in Inuit aged 20 years
and older in 2005–2006 and 2007–2008 suggests that the Inuit
have a statistically significantly lower prevalence of DM than Métis,
First Nations, and their non-indigenous counterparts, which had a
similar burden of disease . Nonetheless, obesity rates among
Canadian Inuit are high, especially among women. Abdominal
adiposity is the prominent form of adiposity among Inuit
women .
Sex difference in the prevalence of DM:  Although no sex
difference in the prevalence of DM was observed in SAMINOR 1,
women had a statistically significantly lower prevalence of DM in
SAMINOR 2. In 2015, the International Diabetes Federation
estimated that adult (20–79 years) men were globally more
affected by DM than women . In 2016, it was estimated that for
every 10 men with DM in Norway, there were eight women with
DM . A higher incidence rate and a different risk factor profile
were observed for men in the fourth survey of the Tromsø Study .
Various risk factors for DM may affect men and women
differently , and the male sex can only be a proxy for them.
Non-fasting plasma glucose in diagnosing diabetics:  In both
SAMINOR 1 and 2, participants were categorized as having DM
based on either self-report or elevated RPG levels
(≥7.5 mmol/L). Medical guidelines accept RPG of ≥11.1 mmol/L in
the presence of classic symptoms of DM as a diagnostic
criterion . The RPG cut-off of 7.5 mmol/L was chosen based on a
validation study by Ziemer et al , in which the authors found that
an RPG cut-off of 7.5 mmol/L gave almost the same sensitivity
(~28%) and positive predictive values (PPV; ~26%) given 75 g oral
glucose tolerance test as standard. At a PPV-to-sensitivity ratio of
1, the most accurate measure of the number of patients in the
population is provided . However, the study by Ziemer et al. was
based on a smaller sample (n=990), with a different age span
(18–75 years), a higher mean BMI (30.4), and a lower prevalence of
DM than in the present study sample. Hence, whether an RPG cut-
off of 7.5 mmol/L yields the same PPV-to-sensitivity ratio in the
present study is unknown. Besides this methodology, the present
study’s data in SAMINOR 2 (where HbA1c results were at hand)
showed a good agreement between RPG cut-off of ≥7.5 mmol/L
and HbA1c of ≥6.5%, the latter being the recommended and
preferred test to diagnose DM (results not shown). As the RPG cut-
off was applied for all sexes and ethnic groups in SAMINOR 1 and
2, the comparison between different groups was probably not
markedly affected.
Questionnaire validity:  The validity of the SAMINOR questions
on diabetes is unknown. The validity of questionnaires varies
considerably according to the setting of the study, the design of
the questionnaire, target population characteristics, and the
burden of the disease . In the Atherosclerosis Risk in
Communities Study in the USA, the sensitivity and PPV of
prevalent, self-reported DM ranged from 58.5% to 70.8% and from
60.4% to 72.3%, respectively, depending on the cut-off used for
fasting plasma glucose (gold standard) and medication use . In
the French CADEUS study, the sensitivity and PPV of self-reported
DM were 86.7% and 73.4%, respectively, using previous medical
history as the gold standard .
Strengths and limitations
The participation rate (54.6% in SAMINOR 1 and 46.3% in
SAMINOR 2) is regarded as acceptable. Due to practical issues in
SAMINOR 2, there was no second opportunity for participants to
be examined, resulting in a lower participation rate compared to
SAMINOR 1. The study was performed in municipalities with a high
proportion of Sami inhabitants, including both coastal and inland
regions. Self-reported ethnicity information enabled comparisons
of Sami and non-Sami. The NPD provided a valid and independent
source of information .
Although the surveys had relatively large overall sample sizes, low
power might be a problem when analyzing subgroups. Due to the
cross-sectional study design, it was not possible to explore the risk
factors for DM in Sami and non-Sami. Inherent to observational
studies like the SAMINOR Study is the possibility that severely
diseased people as well as completely healthy people might not
participate in the survey, which could lead to selection bias. There
is limited knowledge regarding non-responders, except that they
tended to be younger and male. In SAMINOR 1, lower
participation among single people was also observed . This was
in accordance with observed trends in recent Norwegian and
international population-based surveys . Lack of ethnic registry
information from the total source population precluded
assessment of whether the distribution of ethnic groups in the
SAMINOR surveys reflected that of the actual population in the
geographical regions. Participation rates varied across
municipalities. As a consequence, the contribution of the Sami
versus non-Sami from each municipality differed from SAMINOR 1
to SAMINOR 2, which makes the comparison of DM prevalence
between the two studies challenging.
Applying 2-hour post-prandial glucose measurement or fasting
plasma glucose measurements was not feasible in the survey due
to the large number of participants examined throughout the day.
In SAMINOR 1, the portable glycated hemoglobin (HbA1c)
instruments were inadequate for conducting HbA1c measurements
in the buses where clinical examinations took place. Moreover, the
survey took place in provincial areas at long distances from the
medical laboratory. HbA1c was measured in SAMINOR 2, but as
there were not these data for SAMINOR 1, HbA1c was not taken


















In SAMINOR 1, the questions regarding diabetes were congruent.
In SAMINOR 2, contrary to SAMINOR 1, the question about
diabetes was followed by three questions asking the participants
about the type of diabetes they were diagnosed with (T1DM,
T2DM, or gestational diabetes). This difference in methodology
made it more likely that the participants would report DM in
SAMINOR 2. However, in those aged 40–79 years, unpublished
results from the SAMINOR 2 Questionnaire Survey, which had
exactly the same question about diabetes as SAMINOR 1, showed
similar self-reported diabetes prevalence to the SAMINOR 2
Clinical Survey.
Different types of DM (T1DM, T2DM, or gestational DM) were not
distinguished from each other in SAMINOR 1 owing to insufficient
information acquired through questionnaires. Considering that
T2DM accounts for ∼90–95% of those with diabetes , and given
the age of the participants in both studies (40–79 years), most of
the DM cases are expected to be T2DM.
Considering the relatively small number of municipalities included
in this study, it is not certain that the results illustrate the real
health status and disease burden of the Sami as well as other
inhabitants in Northern Norway.
Conclusion
The high prevalence of DM in Sami and non-Sami of both sexes
demands attention and comprehensive prevention measures.
Longitudinal studies with valid endpoint registers are needed in
order to determine the effects of known and unknown risk factors,
and whether these differ in Sami and non-Sami.
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